Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Public ClinicalTrials.gov record NCT00806819. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.
Study identification
- NCT ID
- NCT00806819
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 718 participants
Conditions and interventions
Conditions
Interventions
- Nintedanib (BIBF1120) Drug
- Pemetrexed Drug
- B12 Drug
- dexamethasone (or corticosteroid equivalent) Drug
- placebo Drug
- Folic Acid Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008
- Primary completion
- May 31, 2011
- Completion
- Nov 30, 2015
- Last update posted
- Feb 1, 2017
2008 – 2015
United States locations
- U.S. sites
- 40
- U.S. states
- 19
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Downy | California | — | — |
| Boehringer Ingelheim Investigational Site | Fountain Valley | California | — | — |
| Boehringer Ingelheim Investigational Site | Fullerton | California | — | — |
| Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| Boehringer Ingelheim Investigational Site | Meriden | Connecticut | — | — |
| Boehringer Ingelheim Investigational Site | Aventura | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Boynton Beach | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Jacksonville | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| Boehringer Ingelheim Investigational Site | New Port Richey | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Port Saint Lucie | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Stuart | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Galesburg | Illinois | — | — |
| Boehringer Ingelheim Investigational Site | Skokie | Illinois | — | — |
| Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | — | — |
| Boehringer Ingelheim Investigational Site | New Albany | Indiana | — | — |
| Boehringer Ingelheim Investigational Site | Witchita | Kansas | — | — |
| Boehringer Ingelheim Investigational Site | Ashland | Kentucky | — | — |
| Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| Boehringer Ingelheim Investigational Site | Burlington | Massachusetts | — | — |
| Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | — | — |
| Boehringer Ingelheim Investigational Site | Saint Louis Park | Minnesota | — | — |
| Boehringer Ingelheim Investigational Site | Grand Island | Nebraska | — | — |
| Boehringer Ingelheim Investigational Site | Farmington | New Mexico | — | — |
| Boehringer Ingelheim Investigational Site | Dunkirk | New York | — | — |
| Boehringer Ingelheim Investigational Site | Goshen | New York | — | — |
| Boehringer Ingelheim Investigational Site | Lake Success | New York | — | — |
| Boehringer Ingelheim Investigational Site | Nyack | New York | — | — |
| Boehringer Ingelheim Investigational Site | Asheville | North Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Canton | Ohio | — | — |
| Boehringer Ingelheim Investigational Site | Sandusky | Ohio | — | — |
| Boehringer Ingelheim Investigational Site | Ephrata | Pennsylvania | — | — |
| Boehringer Ingelheim Investigational Site | Langhorne | Pennsylvania | — | — |
| Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| Boehringer Ingelheim Investigational Site | Germantown | Tennessee | — | — |
| Boehringer Ingelheim Investigational Site | Amarillo | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
| Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| Boehringer Ingelheim Investigational Site | Madison | Wisconsin | — | — |
| Boehringer Ingelheim Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 123 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00806819, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2017 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00806819 live on ClinicalTrials.gov.